Global Non-Tyrosine Kinase Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

According to APO Research, The global Non-Tyrosine Kinase Inhibitors market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Non-Tyrosine Kinase Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Non-Tyrosine Kinase Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Non-Tyrosine Kinase Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Non-Tyrosine Kinase Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Non-Tyrosine Kinase Inhibitors include Novartis, Merck KGaA, Roche, Eli Lilly, Pfizer, GlaxoSmithKline (GSK), Onconova Therapeutics, Nerviano Medical Sciences and Jasco Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Non-Tyrosine Kinase Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Non-Tyrosine Kinase Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for Non-Tyrosine Kinase Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Non-Tyrosine Kinase Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Non-Tyrosine Kinase Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Non-Tyrosine Kinase Inhibitors sales, projected growth trends, production technology, application and end-user industry.


Non-Tyrosine Kinase Inhibitors Segment by Company

Novartis
Merck KGaA
Roche
Eli Lilly
Pfizer
GlaxoSmithKline (GSK)
Onconova Therapeutics
Nerviano Medical Sciences
Jasco Pharmaceuticals
Eternity Bioscience
Daiichi Sankyo
Cyclacel Pharmaceuticals
Celgene Corporation
Carna Biosciences
AstraZeneca
Astex Pharmaceuticals
Array BioPharma

Non-Tyrosine Kinase Inhibitors Segment by Type

CDK Inhibitors
mTOR Inhibitors
RAF/MEK Inhibitors

Non-Tyrosine Kinase Inhibitors Segment by Application

Brain Cancer
Respiratory Cancer
Liver Cancer
Others

Non-Tyrosine Kinase Inhibitors Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Tyrosine Kinase Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non-Tyrosine Kinase Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Tyrosine Kinase Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Non-Tyrosine Kinase Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Tyrosine Kinase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Tyrosine Kinase Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Non-Tyrosine Kinase Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Non-Tyrosine Kinase Inhibitors Market Size, 2020 VS 2024 VS 2031
1.3 Global Non-Tyrosine Kinase Inhibitors Market Size Estimates and Forecasts (2020-2031)
1.4 Global Non-Tyrosine Kinase Inhibitors Sales Estimates and Forecasts (2020-2031)
1.5 Global Non-Tyrosine Kinase Inhibitors Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Non-Tyrosine Kinase Inhibitors Market Dynamics
2.1 Non-Tyrosine Kinase Inhibitors Industry Trends
2.2 Non-Tyrosine Kinase Inhibitors Industry Drivers
2.3 Non-Tyrosine Kinase Inhibitors Industry Opportunities and Challenges
2.4 Non-Tyrosine Kinase Inhibitors Industry Restraints
3 Non-Tyrosine Kinase Inhibitors Market by Manufacturers
3.1 Global Non-Tyrosine Kinase Inhibitors Revenue by Manufacturers (2020-2025)
3.2 Global Non-Tyrosine Kinase Inhibitors Sales by Manufacturers (2020-2025)
3.3 Global Non-Tyrosine Kinase Inhibitors Average Sales Price by Manufacturers (2020-2025)
3.4 Global Non-Tyrosine Kinase Inhibitors Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Non-Tyrosine Kinase Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Non-Tyrosine Kinase Inhibitors Manufacturers, Product Type & Application
3.7 Global Non-Tyrosine Kinase Inhibitors Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Non-Tyrosine Kinase Inhibitors Market CR5 and HHI
3.8.2 Global Top 5 and 10 Non-Tyrosine Kinase Inhibitors Players Market Share by Revenue in 2024
3.8.3 2024 Non-Tyrosine Kinase Inhibitors Tier 1, Tier 2, and Tier 3
4 Non-Tyrosine Kinase Inhibitors Market by Type
4.1 Non-Tyrosine Kinase Inhibitors Type Introduction
4.1.1 CDK Inhibitors
4.1.2 mTOR Inhibitors
4.1.3 RAF/MEK Inhibitors
4.2 Global Non-Tyrosine Kinase Inhibitors Sales by Type
4.2.1 Global Non-Tyrosine Kinase Inhibitors Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2031)
4.2.3 Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2020-2031)
4.3 Global Non-Tyrosine Kinase Inhibitors Revenue by Type
4.3.1 Global Non-Tyrosine Kinase Inhibitors Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Non-Tyrosine Kinase Inhibitors Revenue by Type (2020-2031)
4.3.3 Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Type (2020-2031)
5 Non-Tyrosine Kinase Inhibitors Market by Application
5.1 Non-Tyrosine Kinase Inhibitors Application Introduction
5.1.1 Brain Cancer
5.1.2 Respiratory Cancer
5.1.3 Liver Cancer
5.1.4 Others
5.2 Global Non-Tyrosine Kinase Inhibitors Sales by Application
5.2.1 Global Non-Tyrosine Kinase Inhibitors Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Non-Tyrosine Kinase Inhibitors Sales by Application (2020-2031)
5.2.3 Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2020-2031)
5.3 Global Non-Tyrosine Kinase Inhibitors Revenue by Application
5.3.1 Global Non-Tyrosine Kinase Inhibitors Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Non-Tyrosine Kinase Inhibitors Revenue by Application (2020-2031)
5.3.3 Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Application (2020-2031)
6 Global Non-Tyrosine Kinase Inhibitors Sales by Region
6.1 Global Non-Tyrosine Kinase Inhibitors Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Non-Tyrosine Kinase Inhibitors Sales by Region (2020-2031)
6.2.1 Global Non-Tyrosine Kinase Inhibitors Sales by Region (2020-2025)
6.2.2 Global Non-Tyrosine Kinase Inhibitors Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Non-Tyrosine Kinase Inhibitors Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Non-Tyrosine Kinase Inhibitors Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Non-Tyrosine Kinase Inhibitors Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Non-Tyrosine Kinase Inhibitors Revenue by Region
7.1 Global Non-Tyrosine Kinase Inhibitors Revenue by Region
7.1.1 Global Non-Tyrosine Kinase Inhibitors Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Non-Tyrosine Kinase Inhibitors Revenue by Region (2020-2025)
7.1.3 Global Non-Tyrosine Kinase Inhibitors Revenue by Region (2026-2031)
7.1.4 Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Non-Tyrosine Kinase Inhibitors Revenue (2020-2031)
7.2.2 North America Non-Tyrosine Kinase Inhibitors Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Non-Tyrosine Kinase Inhibitors Revenue (2020-2031)
7.3.2 Europe Non-Tyrosine Kinase Inhibitors Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Non-Tyrosine Kinase Inhibitors Revenue (2020-2031)
7.4.2 Asia-Pacific Non-Tyrosine Kinase Inhibitors Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Novartis
8.1.1 Novartis Comapny Information
8.1.2 Novartis Business Overview
8.1.3 Novartis Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Novartis Non-Tyrosine Kinase Inhibitors Product Portfolio
8.1.5 Novartis Recent Developments
8.2 Merck KGaA
8.2.1 Merck KGaA Comapny Information
8.2.2 Merck KGaA Business Overview
8.2.3 Merck KGaA Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Merck KGaA Non-Tyrosine Kinase Inhibitors Product Portfolio
8.2.5 Merck KGaA Recent Developments
8.3 Roche
8.3.1 Roche Comapny Information
8.3.2 Roche Business Overview
8.3.3 Roche Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Roche Non-Tyrosine Kinase Inhibitors Product Portfolio
8.3.5 Roche Recent Developments
8.4 Eli Lilly
8.4.1 Eli Lilly Comapny Information
8.4.2 Eli Lilly Business Overview
8.4.3 Eli Lilly Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Eli Lilly Non-Tyrosine Kinase Inhibitors Product Portfolio
8.4.5 Eli Lilly Recent Developments
8.5 Pfizer
8.5.1 Pfizer Comapny Information
8.5.2 Pfizer Business Overview
8.5.3 Pfizer Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Pfizer Non-Tyrosine Kinase Inhibitors Product Portfolio
8.5.5 Pfizer Recent Developments
8.6 GlaxoSmithKline (GSK)
8.6.1 GlaxoSmithKline (GSK) Comapny Information
8.6.2 GlaxoSmithKline (GSK) Business Overview
8.6.3 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Product Portfolio
8.6.5 GlaxoSmithKline (GSK) Recent Developments
8.7 Onconova Therapeutics
8.7.1 Onconova Therapeutics Comapny Information
8.7.2 Onconova Therapeutics Business Overview
8.7.3 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Product Portfolio
8.7.5 Onconova Therapeutics Recent Developments
8.8 Nerviano Medical Sciences
8.8.1 Nerviano Medical Sciences Comapny Information
8.8.2 Nerviano Medical Sciences Business Overview
8.8.3 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Product Portfolio
8.8.5 Nerviano Medical Sciences Recent Developments
8.9 Jasco Pharmaceuticals
8.9.1 Jasco Pharmaceuticals Comapny Information
8.9.2 Jasco Pharmaceuticals Business Overview
8.9.3 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio
8.9.5 Jasco Pharmaceuticals Recent Developments
8.10 Eternity Bioscience
8.10.1 Eternity Bioscience Comapny Information
8.10.2 Eternity Bioscience Business Overview
8.10.3 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Product Portfolio
8.10.5 Eternity Bioscience Recent Developments
8.11 Daiichi Sankyo
8.11.1 Daiichi Sankyo Comapny Information
8.11.2 Daiichi Sankyo Business Overview
8.11.3 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Product Portfolio
8.11.5 Daiichi Sankyo Recent Developments
8.12 Cyclacel Pharmaceuticals
8.12.1 Cyclacel Pharmaceuticals Comapny Information
8.12.2 Cyclacel Pharmaceuticals Business Overview
8.12.3 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio
8.12.5 Cyclacel Pharmaceuticals Recent Developments
8.13 Celgene Corporation
8.13.1 Celgene Corporation Comapny Information
8.13.2 Celgene Corporation Business Overview
8.13.3 Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Celgene Corporation Non-Tyrosine Kinase Inhibitors Product Portfolio
8.13.5 Celgene Corporation Recent Developments
8.14 Carna Biosciences
8.14.1 Carna Biosciences Comapny Information
8.14.2 Carna Biosciences Business Overview
8.14.3 Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 Carna Biosciences Non-Tyrosine Kinase Inhibitors Product Portfolio
8.14.5 Carna Biosciences Recent Developments
8.15 AstraZeneca
8.15.1 AstraZeneca Comapny Information
8.15.2 AstraZeneca Business Overview
8.15.3 AstraZeneca Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.15.4 AstraZeneca Non-Tyrosine Kinase Inhibitors Product Portfolio
8.15.5 AstraZeneca Recent Developments
8.16 Astex Pharmaceuticals
8.16.1 Astex Pharmaceuticals Comapny Information
8.16.2 Astex Pharmaceuticals Business Overview
8.16.3 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.16.4 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio
8.16.5 Astex Pharmaceuticals Recent Developments
8.17 Array BioPharma
8.17.1 Array BioPharma Comapny Information
8.17.2 Array BioPharma Business Overview
8.17.3 Array BioPharma Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.17.4 Array BioPharma Non-Tyrosine Kinase Inhibitors Product Portfolio
8.17.5 Array BioPharma Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Non-Tyrosine Kinase Inhibitors Value Chain Analysis
9.1.1 Non-Tyrosine Kinase Inhibitors Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Non-Tyrosine Kinase Inhibitors Production Mode & Process
9.2 Non-Tyrosine Kinase Inhibitors Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Non-Tyrosine Kinase Inhibitors Distributors
9.2.3 Non-Tyrosine Kinase Inhibitors Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings